Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.50p +1.23% 123.50p 122.00p 125.00p 123.50p 122.00p 122.00p 17,934 12:05:43
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -6.0 -0.3 - 63.43

Verona Pharma Share Discussion Threads

Showing 12651 to 12672 of 12675 messages
Chat Pages: 507  506  505  504  503  502  501  500  499  498  497  496  Older
DateSubjectAuthorDiscuss
17/8/2017
20:53
hTTp://www.veronapharma.com/uploads/downloads/vrp-investor-presentation-august-2017-1502711536.pdf
bewise2
09/8/2017
18:26
Tip Update: Buy at 119p @ 9 Aug 2017 Tip style SPECULATIVE Risk rating HIGH Timescale LONG TERM Our previous tip We said BUY at 175p (adjusted for 50:1 share consolidation) on 22 Sep 2016 Tip performance to date -32% By Megan Boxall Verona Pharma’s (VRP) busy six months of drug development has come at a cost to the bottom line. A spike in research and development expenditure in the six months to June 2017 widened operating losses from £1.9m to £10.9m. But an increase in shares in issue meant losses per share were softer at 7.3p, compared with 8.7p in 2016. As biotechnology companies go, there is a lot to like about Verona. Its novel respiratory drug, RPL554, is undergoing several different clinical trials including two studies in Europe: one to assess appropriate dosing and one in combination with another regularly used respiratory drug. There is also an early-stage study in the US. Meanwhile, the net cash balance is healthy at £95m thanks to the group’s recent Nasdaq IPO. IC View Verona is making steady progress in an exciting part of the respiratory market and given its healthy pile of cash, we see no reason – aside from the risk of further fundraising, which looks remote – to change our buy call, at 119p. Buy. Last IC View: Buy, 133p, 2 May 2017
gersemi
05/8/2017
13:16
Summary hTTp://www.veronapharma.com/uploads/downloads/vrp-jefferies-020617-002-14969380111-1498615667.pdf
bewise2
26/7/2017
16:26
...and no effect on share price ..
haff1
26/7/2017
08:36
RNS hTTp://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/VRP/13307334.html
bewise2
25/7/2017
15:18
..this has been jam tomorrow for so so long and constantly wilting in share price Hopefully it will one day show some lasting upward trend?
haff1
23/7/2017
09:51
Just noticed this from a RNS back in April....hopefully things will be on the up in 2018....... hTTps://www.investegate.co.uk/arix-bioscience-plc/rns/group-business-verona-receives-ind-for-rpl554/201704181200046007C/ Joe Anderson, Chief Executive Officer of Arix Bioscience Plc, commented:"Verona is a dynamic company with an important drug asset, which we believe has the potential to address significant unmet needs in respiratory medicine.  RPL554 has shown potential in COPD and cystic fibrosis. This authorisation by the FDA puts it on a path towards advancing this promising candidate towards approval."  
bewise2
13/7/2017
11:45
HTTP://investors.veronapharma.com/static-files/794b4b7f-0ce7-4203-81c0-c93ec4c2860c
bewise2
27/6/2017
08:30
Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today regulatory approval in five European countries, comprising the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic, for a Phase 2b dose-ranging trial of RPL554 for maintenance treatment of chronic obstructive pulmonary disease (COPD). The trial is expected to commence in the third quarter of 2017, with top-line data expected in the second half of 2018.
bewise2
23/6/2017
17:37
Anybody intending to go to the shareholders meeting next week?
bewise2
23/6/2017
08:31
Is this a new low for the share price
kwizza
23/6/2017
08:10
American adventure turned sour?
ewads
24/5/2017
16:13
Equities research analysts at Stifel Nicolaus assumed coverage on shares of Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) in a research note issued on Monday. The firm set a “buy” rating and a $22.00 price target on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 35.30% from the company’s current price
aishah
24/5/2017
15:38
Pleased to see 150p barrier broken. Time for a partial EIS exit and let the rest run.
127tolmers
23/5/2017
15:17
May 23, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announced today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the Jefferies 2017 Global Healthcare Conference. An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
bewise2
23/5/2017
10:28
Nasdaq listing and placing all done. City switches from short to long. C'est tout simple.
phowdo
23/5/2017
10:13
Jefferies International initiated with a BUY and 250p target.
aishah
23/5/2017
10:03
What is occurring?
bonzo
28/4/2017
07:50
The Nasdaq ticker is VRNA http://www.nasdaq.com/symbol/vrna I'll have a go at changing the header to accommodate an additional real time Nasdaq chart.
timbo003
27/4/2017
10:06
A floor of 132p has now been set by the NASDAQ offer. Hopefully the price quickly moves to a 15% premium post offer and breaks through the 150p barrier and provides a sensible post EIS exit price.
127tolmers
26/4/2017
00:34
http://www.nasdaq.com/markets/ipos/company/verona-pharma-plc-999545-83296
bewise2
19/4/2017
09:26
http://m.nasdaq.com/article/respiratory-biotech-verona-pharma-sets-terms-for-75-million-us-ipo-cm775580
bewise2
Chat Pages: 507  506  505  504  503  502  501  500  499  498  497  496  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170818 18:14:25